Allogene Tumbles 9.96% as Bearish Tech Outweighs Analyst Optimism

Market Snapshot

Allogene (ALLO.O) is currently trading with a steep price decline of -9.96% in recent periods, and technical indicators suggest a weak trend with an internal diagnostic score (0-10) of just 2.0, signaling that caution is warranted.

News Highlights

• March 24, 2026 - UCB selects Georgia for a new biologics manufacturing facility: This $5 billion investment highlights a growing commitment to U.S. biotech manufacturing, which could indirectly benefit Allogene by reinforcing the sector’s long-term potential.
• March 24, 2026 - BioNTech highlights late-stage lung cancer portfolio at ELCC 2026: While this news primarily affects other players, it underlines the ongoing innovation and clinical progress in the biotech sector, which may provide some optimism for investors in Allogene.
• March 24, 2026 - DAFNA Capital trims iShares Biotechnology ETF stake: This move could signal a broader shift in institutional positioning within the biotech space, which might indirectly impact Allogene’s investor sentiment.

Analyst Views & Fundamentals

Analyst Views

Over the past 20 days, two analysts—John Newman (Canaccord Genuity) and Biren Amin (Piper Sandler)—have issued ratings for Allogene. The simple average rating score is 4.50, while the performance-weighted rating is 3.93. Both analysts have maintained 100% historical accuracy in their previous predictions, though their current ratings (Strong Buy and Buy) show some dispersion. These optimistic signals appear to contrast with the recent 9.96% price drop, suggesting a mismatch between analyst expectations and market behavior.

Fundamentals

Allogene’s recent fundamental performance reveals mixed signals. Key fundamental factors include:

• Gross profit margin: 41.86% (model score: 2.81)
• Inventory turnover ratio: 105.84 (model score: 4.19)
• Cost of sales ratio: 64.19% (model score: 3.00)
• Asset-MV: -0.55 (model score: 3.66)
• Cash-MV: 0.02 (model score: 3.09)
• Profit-MV: 0.66 (model score: 3.16)
• Revenue-MV: -0.09 (model score: 0.00)

While some metrics like inventory turnover suggest efficient asset use, the weak revenue and asset metrics indicate underlying challenges in the business model or valuation. The internal diagnostic score for the overall fundamental model is 2.81—slightly better than the technical score, but still below average.

Money-Flow Trends

Allogene has seen a positive flow of institutional capital, with 57.63% of total inflow attributed to large and extra-large investors. The fund-flow model assigned an excellent score of 8.1, indicating strong support from big-money players despite the recent price drop. In contrast, retail investor activity remains neutral, with small investors showing a slight inflow of 50.46%. This contrast highlights the growing confidence from institutional money while retail traders remain cautious.

Key Technical Signals

Allogene’s technical outlook remains bearish, with a score of 2.0 and 4 bearish indicators outweighing 0 bullish ones. Recent chart patterns include:

• Bullish Harami Cross (score: 2.41): This pattern has historically been neutral in direction and has shown a poor win rate of 42.86% and an average return of -5.80%.
• Long Upper Shadow (score: 1.36): A bearish sign indicating indecision and downward pressure, with a 38.81% win rate and an average return of 8.00%.
• Piercing Pattern (score: 1.00): Another bearish signal, this one with an average return of -3.17% and a 0% win rate.
• 
• Dark Cloud Cover (score: 3.21): A neutral-to-bearish pattern with a 50% win rate and an average return of -1.32%.

These signals, especially the low score for the Piercing Pattern, indicate a weak momentum. Over the past five days, these bearish patterns have appeared consistently, reinforcing the current negative trend. The internal diagnostic score of 2.0 suggests the stock is in a fragile state and not currently recommended for aggressive investment.

Conclusion

Allogene is facing a confluence of bearish technical signals and mixed fundamental performance, despite some analyst optimism and positive institutional inflows. With a technical score of 2.0 and a recent price drop of 9.96%, we recommend a cautious approach. Investors should consider waiting for a clearer breakout or positive earnings reports before committing to long positions. For now, monitoring institutional activity and fundamental progress may offer more strategic value than direct stock purchases.